CARB-X Awards $2.6 Million to AdJane for Gonorrhea Vaccine Development

CARB-X, a global partnership aiming to tackle antibiotic-resistant bacteria, has funded the Dutch company AdJane with $2.6 million. This funding supports the advancement of a vaccine candidate to prevent infections by Neisseria gonorrhoeae, the bacterium responsible for gonorrhea. Gonorrhea is a prevalent sexually transmitted infection, causing over 80 million new cases annually and potentially leading to severe complications such as infertility and heightened HIV risk.

The AdJane vaccine, developed using its nOMV platform, aims to combat antimicrobial resistance and facilitate global health improvements. The platform employs a heterologous approach that targets and broadens immune responses against N. gonorrhoeae. This initiative builds on prior Phase I trials that demonstrated the vaccine's safety in humans.

The funding for CARB-X is supported by various international bodies, including U.S. and UK institutions, ensuring continued investment in combating drug-resistant bacteria. AdJane seeks to deliver comprehensive and targeted immune protection through a streamlined development and manufacturing process.